Conmed Q1 2024 Adj EPS $0.79 Beats $0.74 Estimate, Sales $312.273M Beat $306.776M Estimate
Portfolio Pulse from Benzinga Newsdesk
Conmed (NYSE:CNMD) reported Q1 2024 adjusted EPS of $0.79, surpassing the $0.74 estimate, and sales of $312.273M, exceeding the $306.776M estimate. This represents a 19.7% increase in EPS and a 5.69% increase in sales from the same period last year.
April 24, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Conmed's Q1 2024 earnings and sales exceeded analyst estimates, with a notable year-over-year growth in both metrics.
Conmed's better-than-expected Q1 2024 earnings and sales figures indicate strong financial health and operational efficiency, likely leading to positive investor sentiment and a potential increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100